{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "RYTM",
  "name": "Rhythm Pharmaceuticals, Inc.",
  "url": "https://frontierpicks.com/dossiers/RYTM/",
  "json_url": "https://frontierpicks.com/dossiers/RYTM.json",
  "status": "WATCHLIST",
  "current_conviction": "MEDIUM",
  "view_source": "research",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Rhythm Pharmaceuticals is modestly more likely than not to beat the S&P 500 over three months: AstraZeneca's reported $124-a-share proposal sits above the $116.61 close of 17 November 2026, and Imcivree sales grew 80% in the third quarter. A signed merger agreement, or an end to talks before the fourth-quarter report of early 2027, settles it.",
  "invalidation_trigger": "A daily close below $100, which would give back most of the gain since AstraZeneca's proposal was reported on 2026-11-04 and show the market pricing an end to talks; or a statement by Rhythm or AstraZeneca that talks have ended with no other bidder named.",
  "kill_line_kind": "price_line",
  "kill_line_due": null,
  "catalyst_date": "2026-12-31",
  "catalyst_estimated": true,
  "portfolio": null,
  "pick": null,
  "themes": [
    "rare-disease-gene-therapy"
  ],
  "tags": [],
  "sources": [],
  "caveats": [
    {
      "claim": "The reported AstraZeneca proposal is non-binding, and neither company has confirmed it; part of the reported $134 a share depends on milestone payments.",
      "source": "Reuters report, 2026-11-04",
      "as_of": "2026-11-04"
    },
    {
      "claim": "The $320.9 million cash figure at 2026-09-30 excludes a $250 million initial term-loan draw and a $70 million payment due to LG Chem for bivamelagon.",
      "source": "Rhythm third-quarter 2026 results, Form 8-K filed 2026-11-03",
      "as_of": "2026-11-03"
    }
  ],
  "source_links": [
    {
      "title": "AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say",
      "url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-made-10-billion-bid-213058831.html",
      "date": "2026-11-04"
    },
    {
      "title": "RHYTHM PHARMACEUTICALS, INC. - Form 8-K - FY2026",
      "url": "https://www.sec.gov/Archives/edgar/data/0001649904/000162828026069106/q32026earningspr.htm",
      "date": null
    },
    {
      "title": "AstraZeneca said to offer $10B to acquire Rhythm, analysts whisper of a bidding war",
      "url": "https://www.fiercepharma.com/pharma/astrazeneca-offers-10b-acquire-rhythm-analysts-whisper-bidding-war",
      "date": null
    },
    {
      "title": "RHYTHM PHARMACEUTICALS, INC. - Form 10-Q - FY2026",
      "url": "https://www.sec.gov/Archives/edgar/data/0001649904/000162828026069485/rytm-20260930.htm",
      "date": null
    },
    {
      "title": "Rhythm Pharmaceuticals Reports Q3 2026: Revenue of $92.1 Million Misses Estimates, EPS Loss of $(0.61) Beats Expectations",
      "url": "https://www.gurufocus.com/news/9165599/rhythm-pharmaceuticals-reports-q3-2026-revenue-of-921-million-misses-estimates-eps-loss-of-061-beats-expectations",
      "date": null
    },
    {
      "title": "AstraZeneca made a $10bn offer to buy Rhythm Pharmaceuticals",
      "url": "https://www.marketscreener.com/news/latest/AstraZeneca-made-a-10bn-offer-to-buy-Rhythm-Pharmaceuticals-54664321/",
      "date": null
    }
  ],
  "evidence": [
    {
      "claim": "Third-quarter 2026 net product revenue was $92.1 million, up 29% from the previous quarter, against $51.3 million a year earlier; US sales were $67.5 million and ex-US sales $24.7 million.",
      "source": "Rhythm third-quarter 2026 results, Form 8-K filed 2026-11-03",
      "as_of": "2026-11-03"
    },
    {
      "claim": "Rhythm had received more than 700 patient start forms for Imcivree in acquired hypothalamic obesity from more than 500 prescribers by 2026-09-30.",
      "source": "Rhythm third-quarter 2026 results, Form 8-K filed 2026-11-03",
      "as_of": "2026-09-30"
    },
    {
      "claim": "AstraZeneca made a non-binding proposal of up to $134 a share including milestones, about $10 billion in total; the Wall Street Journal reported a $124-a-share offer made in October.",
      "source": "Reuters, 2026-11-04",
      "as_of": "2026-11-04"
    },
    {
      "claim": "Rhythm shares closed up 28% at $110.68 on the day the AstraZeneca proposal was reported.",
      "source": "Reuters, 2026-11-04",
      "as_of": "2026-11-04"
    },
    {
      "claim": "Cash, cash equivalents and short-term investments were $320.9 million at 2026-09-30, which the company says funds planned operations for at least 24 months.",
      "source": "Rhythm third-quarter 2026 results, Form 8-K filed 2026-11-03",
      "as_of": "2026-09-30"
    },
    {
      "claim": "Gross margin was 86.8% in the quarter to 2026-09-30, against 91.6% in the quarter to 2025-12-31.",
      "source": "Form 10-Q for the third quarter of 2026",
      "as_of": "2026-11-03"
    },
    {
      "claim": "CEO David Meeker sold 50,000 shares at an average $102.67 on 2026-09-14 under a Rule 10b5-1 plan, after exercising options at $6.05.",
      "source": "SEC Form 4, 2026-09-14",
      "as_of": "2026-09-14"
    },
    {
      "claim": "CFO Hunter Smith sold 62,774 shares at an average $105.46 on 2026-08-31 under a Rule 10b5-1 plan, after exercising options at $25.79.",
      "source": "SEC Form 4, 2026-09-01",
      "as_of": "2026-08-31"
    }
  ],
  "view_changes": [],
  "frame": {
    "as_of": "2026-11-18",
    "business": "Rhythm Pharmaceuticals sells Imcivree (setmelanotide), a daily injection for rare forms of obesity: Bardet-Biedl syndrome, certain genetic deficiencies and, since 2026-03-19 in the US, acquired hypothalamic obesity. It sells through specialty channels in the US, Europe and Japan. Net product revenue was $92.1 million in the quarter to 2026-09-30, with 73% of it from the US.",
    "change": {
      "now": "On 2026-11-04 Reuters and the Wall Street Journal reported a non-binding AstraZeneca proposal of $124 a share upfront, up to $134 with milestones (about $10 billion). A report of a second bidder followed on 2026-11-06.",
      "next": "Without a deal, Rhythm funds itself: $320.9 million in cash on 2026-09-30 (before a $250 million term-loan draw and a $70 million LG Chem payment), 2026 non-GAAP operating spending guided at $360–380 million.",
      "linked": "AstraZeneca (AZN) would gain a rare-obesity franchise for its Alexion unit. Novo Nordisk (NVO), the obesity-drug leader named in deal coverage, faces a larger rival in rare obesity if a deal is signed."
    },
    "priced_in": "At the 2026-11-17 close (filed inputs to 2026-11-03) the shares trade at EV/sales 28.0 and P/B 91.9, for an enterprise value of $7,866 million; EV/EBIT and P/E are not meaningful. That holds only if revenue keeps growing near the 79.6% of the latest filed quarter while the −42.6% operating margin turns positive, or if the reported AstraZeneca proposal becomes a signed deal.",
    "priced_in_filed": null,
    "links": {
      "customers": [],
      "suppliers": [],
      "competitors": [
        {
          "ticker": "NVO",
          "url": "https://frontierpicks.com/dossiers/NVO/"
        }
      ]
    }
  },
  "filed_numbers": {
    "as_of": "2026-11-20",
    "sector": "Healthcare",
    "financials": {
      "status": "ok",
      "reason": null,
      "close_date": "2026-11-20",
      "latest_quarter": "2026-09-30",
      "figures": {
        "revenue": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-11-03",
              "restated": null,
              "value_musd": 92.1,
              "yoy_pct": 79.6
            },
            {
              "end": "2026-06-30",
              "filed": "2026-08-04",
              "restated": null,
              "value_musd": 71.3,
              "yoy_pct": 46.9
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-05",
              "restated": null,
              "value_musd": 60.1,
              "yoy_pct": 83.8
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-26",
              "restated": null,
              "value_musd": 57.3,
              "yoy_pct": 36.9
            },
            {
              "end": "2025-09-30",
              "filed": "2025-11-04",
              "restated": null,
              "value_musd": 51.3,
              "yoy_pct": 54.3
            },
            {
              "end": "2025-06-30",
              "filed": "2025-08-05",
              "restated": null,
              "value_musd": 48.5,
              "yoy_pct": 66.8
            }
          ]
        },
        "gross_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-11-03",
              "restated": null,
              "pct": 86.8
            },
            {
              "end": "2026-06-30",
              "filed": "2026-08-04",
              "restated": null,
              "pct": 87.5
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-05",
              "restated": null,
              "pct": 88.1
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-26",
              "restated": null,
              "pct": 91.6
            },
            {
              "end": "2025-09-30",
              "filed": "2025-11-04",
              "restated": null,
              "pct": 89.3
            },
            {
              "end": "2025-06-30",
              "filed": "2025-08-05",
              "restated": null,
              "pct": 88.6
            }
          ]
        },
        "operating_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-11-03",
              "restated": null,
              "pct": -42.6
            },
            {
              "end": "2026-06-30",
              "filed": "2026-08-04",
              "restated": null,
              "pct": -68.1
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-05",
              "restated": null,
              "pct": -87.1
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-26",
              "restated": null,
              "pct": -82.2
            },
            {
              "end": "2025-09-30",
              "filed": "2025-11-04",
              "restated": null,
              "pct": -102.6
            },
            {
              "end": "2025-06-30",
              "filed": "2025-08-05",
              "restated": null,
              "pct": -93.4
            }
          ]
        },
        "pretax_income": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-03",
          "value_musd": -40.8
        },
        "net_income": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-03",
          "four_quarters_end": "2026-09-30",
          "value_musd": -41.4,
          "four_quarters_musd": -193.8
        },
        "operating_cash_flow": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-03",
          "first_end": "2025-12-31",
          "value_musd": -81.8
        },
        "capital_spending": {
          "status": "not available"
        },
        "free_cash_flow": {
          "status": "not available"
        },
        "diluted_share_change": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-03",
          "base_end": "2025-09-30",
          "pct": 4.2
        },
        "cash": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-03",
          "value_musd": 320.9
        },
        "debt": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-03",
          "value_musd": 102.7,
          "composition": "non-current long-term debt plus current maturities"
        },
        "net_cash": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-03",
          "value_musd": 218.2
        },
        "deferred_revenue": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-03",
          "value_musd": 0,
          "yoy_pct": null
        },
        "backlog": {
          "status": "not reported"
        },
        "receivables": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-03",
          "value_musd": 39.1
        },
        "inventory": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-03",
          "value_musd": 31.2
        },
        "equity": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-03",
          "value_musd": 88
        },
        "market_value": {
          "status": "ok",
          "close_date": "2026-11-20",
          "basis_end": "2026-11-02",
          "basis_filed": "2026-11-03",
          "value_musd": 7790
        },
        "enterprise_value": {
          "status": "ok",
          "close_date": "2026-11-20",
          "basis_end": "2026-11-02",
          "basis_filed": "2026-11-03",
          "value_musd": 7571.8
        },
        "ev_sales": {
          "status": "ok",
          "close_date": "2026-11-20",
          "basis_end": "2026-11-02",
          "basis_filed": "2026-11-03",
          "multiple": 27
        },
        "ev_ebit": {
          "status": "not meaningful"
        },
        "pe": {
          "status": "not meaningful"
        },
        "pb": {
          "status": "ok",
          "close_date": "2026-11-20",
          "basis_end": "2026-11-02",
          "basis_filed": "2026-11-03",
          "multiple": 88.6
        },
        "fcf_yield": {
          "status": "not available"
        }
      }
    },
    "short_interest": {
      "status": "ok",
      "settlement": "2026-10-30",
      "published": "2026-11-10",
      "short_pct_of_outstanding": 16.84,
      "days_to_cover": 23.3,
      "change_pct": 6.1
    },
    "insiders": {
      "status": "not available yet",
      "as_of": null,
      "windows": []
    }
  },
  "body_markdown": "## Current Thesis\n\nRhythm Pharmaceuticals is rated Medium: the shares are modestly more likely than not to beat the S&P 500 over the next three months. AstraZeneca's reported takeover proposal of $124 a share upfront sits above the $116.61 close of 2026-11-17, and the business behind it grew sales 80% from a year earlier in the third quarter. A signed merger agreement, or a statement that talks have ended, settles the call. No date is set for either.\n\nThe case rests on a proposal that neither company has confirmed. Reuters reported on 2026-11-04 that AstraZeneca made a non-binding offer worth about $10 billion, up to $134 a share including milestone payments. The Wall Street Journal reported the same day that the $124 offer was made in October. Analysts at Jefferies, Leerink and William Blair told Fierce Pharma that a bidding war could follow and that Rhythm is unlikely to accept the current terms. A report of an additional bidder followed on 2026-11-06.\n\nThe standalone business supports a floor under the price that sits well above where the shares traded before the reports. Imcivree (setmelanotide) is now approved in the US for acquired hypothalamic obesity, and that launch drove a 32% rise in US sales from the previous quarter in the quarter to 2026-09-30, the company's 8-K of 2026-11-03 shows.\n\nThe rating is Medium rather than High because the outcome is two-sided. A signed deal at or above the reported price would most likely carry the shares past the index. If talks collapse, the shares lose most of the gain from the 2026-11-04 report.\n\n## Bull Case\n\n- **Reported offer sits above the price.** The Wall Street Journal reported a $124-a-share AstraZeneca offer, and Reuters reported up to $134 including milestones, on 2026-11-04. The shares closed at $116.61 on 2026-11-17.\n- **Signs of competing interest.** Company news on 2026-11-06 carried a report of an additional bidder. Jefferies, Leerink and William Blair analysts said a bidding war could be brewing, Fierce Pharma reported in early November 2026.\n- **Hypothalamic obesity launch is working.** Rhythm had more than 700 patient start forms for acquired hypothalamic obesity from more than 500 prescribers by 2026-09-30, about six months after the FDA approval of 2026-03-19, its third-quarter 8-K shows.\n- **Revenue growth is speeding up.** Third-quarter 2026 net product revenue was $92.1 million, against $51.3 million a year earlier, and nine-month revenue was $223.5 million against $137.5 million, the 8-K of 2026-11-03 reports. The operating margin narrowed to −42.6% in the quarter from −102.6% a year earlier, filed figures show.\n- **More markets and indications are coming.** Japan launched Imcivree for acquired hypothalamic obesity on 2026-10-13, Health Canada approved it on 2026-09-22, and NICE (England's National Institute for Health and Care Excellence) issued positive guidance for adults with Bardet-Biedl syndrome on 2026-11-04. Rhythm guides to a pivotal Phase 3 start for its oral drug bivamelagon in acquired hypothalamic obesity by the end of 2026.\n\n## Bear Case\n\n- **The proposal is unconfirmed and non-binding.** Neither Rhythm nor AstraZeneca has commented on the reports of 2026-11-04. Part of the reported $134 depends on milestones, so the guaranteed portion is the $124 the Wall Street Journal cited.\n- **Revenue fell short of the analyst estimate.** Third-quarter revenue of $92.1 million came in below the $98.74 million analyst estimate, GuruFocus reported on 2026-11-03.\n- **Gross margin is slipping.** Gross margin fell to 86.8% in the quarter to 2026-09-30, from 91.6% in the quarter to 2025-12-31, filed figures show.\n- **Losses and dilution continue.** Net loss was $41.4 million in the third quarter and $194 million over the four quarters to 2026-09-30. The diluted share count rose 4.2% from a year earlier, and operating cash flow was −$82 million over those four quarters, the 10-Q filed 2026-11-03 shows.\n- **Insiders sold below the reported offer.** Chief Executive David Meeker sold 50,000 shares at an average $102.67 on 2026-09-14, and Chief Financial Officer Hunter Smith sold 62,774 shares at an average $105.46 on 2026-08-31, both under Rule 10b5-1 plans and after option exercises, SEC Form 4 filings show.\n\n## Setup & Price Structure\n\nThe shares closed at $116.61 on 2026-11-17, up from $107.48 on 2026-11-16. That was the session after Rhythm released new clinical data for setmelanotide in acquired hypothalamic obesity. The closes from 2026-11-10 to 2026-11-17 ranged from $107.48 to $116.61, all above the $110.68 close of 2026-11-04 except two sessions. On 2026-11-04 the shares rose 28% on the takeover report, Reuters reported.\n\nThe reported $124 upfront price sits above the last close, and the 52-week intraday high is $122.20, set on 2025-12-11. The 50-day moving average is $97.27 and the 200-day moving average is $97.31, both as of 2026-11-17. The 52-week closing low is $75.82, set on 2026-03-27.\n\nThe 3-month change is 0.8%, against a reference close of $115.73 on 2026-08-19. The shares fell between August and early November and recovered on the takeover report. For stocks after a one-day jump of this size, no reliable effect on the following one or three months has been found so far. A common market view is that a gap between a stock's price and a reported offer measures how much the market doubts the deal. Here that gap is the distance between the $116.61 close and the reported $124.\n\n## Catalyst Calendar\n\n- **~2026-12-31 (est.):** Start of the pivotal Phase 3 trial of bivamelagon in acquired hypothalamic obesity, guided for year-end 2026. Shows whether the oral follow-on to Imcivree stays on schedule. Its timing feeds into what a bidder pays and what the standalone pipeline is worth.\n- **~2027-01 (est.):** Preliminary fourth-quarter and full-year 2026 net product revenue. The first read on whether hypothalamic obesity demand keeps lifting US sales above the $67.5 million of the third quarter. That matters most if no deal is signed.\n- **~2027-02 (est.):** Fourth-quarter and full-year 2026 results and 2027 guidance. This report sets the standalone case if talks with AstraZeneca have not produced a signed agreement by then.\n\n## What Would Change Our Mind\n\nA daily close below $100, which would give back most of the gain since AstraZeneca's proposal was reported on 2026-11-04 and show the market pricing an end to talks; or a statement by Rhythm or AstraZeneca that talks have ended with no other bidder named.\n\nThe risks this note tracks, each with what would confirm it:\n\n- Talks with AstraZeneca end without a signed agreement and no rival bidder appears. Confirmed by: A statement by either company that discussions have ended, or a report that AstraZeneca has withdrawn its proposal.\n- A deal is signed at terms close to the current price, with much of the value in contingent milestone payments. Confirmed by: An announced merger agreement whose upfront cash price is at or below the $124 the Wall Street Journal reported, with the rest paid as contingent value rights.\n- The hypothalamic obesity launch slows after its first two quarters. Confirmed by: Fourth-quarter 2026 US net product revenue at or below the $67.5 million of the third quarter.\n- Gross margin keeps falling as the sales mix and ex-US pricing shift. Confirmed by: Fourth-quarter 2026 gross margin below the 86.8% filed for the third quarter.\n- Without a deal, losses and new debt lead to further dilution. Confirmed by: An equity offering, or a diluted share count rising faster than the 4.2% from a year earlier filed for the third quarter of 2026.\n\n## Correlation Notes\n\nThe shares now trade on news about the takeover more than on the S&P 500 or the biotech sector. Reports on AstraZeneca (AZN) and its rare-disease unit Alexion, and any word of a rival bidder, move them most. Reuters reported on 2026-11-04 that AstraZeneca, valued at about $292 billion, would pursue the deal through Alexion.\n\nNovo Nordisk (NVO) is named in deal coverage as the large obesity-drug competitor. Rhythm's market differs from Novo's mass-market drugs: it sells to patients with rare genetic and acquired forms of obesity. Without a deal, the shares would trade on Imcivree's quarterly sales and on bivamelagon's Phase 3 progress.",
  "first_seen": "2026-11-17",
  "last_analyzed": "2026-11-18T03:38:15+00:00",
  "last_synthesized": "2026-11-18",
  "date_modified": "2026-11-18",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}